Editorial Policy & Evidence Standards (E-E-A-T)

Published by the OncoGuides Clinical Governance Board

1. Commitment to Evidence-Based Medicine

CardioOncoGuides produces content grounded strictly in peer-reviewed clinical cardiology and oncology research, international societal consensus statements, and randomized controlled trial data. Our clinical synthesis reflects authoritative guidance from:

European Society of Cardiology (ESC) — 2022 Guidelines on Cardio-Oncology
International Cardio-Oncology Society (IC-OS) — Global Consensus Statements
American Heart Association (AHA) & American College of Cardiology (ACC)
American Society of Clinical Oncology (ASCO) — Cardiotoxicity Prevention Guidelines

2. Clinical Evidence Hierarchy

We classify all recommendations using standard international evidence hierarchies:

Level A: Supported by multiple randomized controlled clinical trials or meta-analyses (e.g., STOP-CA trial, OVERCOME trial, Cardinale et al.).
Level B: Supported by single randomized trials or large prospective registry cohorts.
Level C: Supported by expert consensus, mechanistic pharmacology, and observational studies.

3. Commercial Independence & Non-Bias

CardioOncoGuides maintains complete editorial independence. We do not accept pharmaceutical sponsorship, paid product placements, or commercial endorsements. All cardioprotective drugs (Dexrazoxane, Carvedilol, Lisinopril, Empagliflozin, Atorvastatin) are presented purely on clinical efficacy and safety merits.

4. Financial Aid & Non-Profit Verification

Our non-profit assistance directory is verified on a recurring schedule to confirm active registration with national charity regulators (such as the US 501(c)(3) IRS registry, the UK Charity Commission, or equivalent international bodies).